What's happened
Weight-loss GLP-1 drugs are expanding beyond injections to pills in the US, UK and UAE. Major manufacturers report rising uptake and ongoing development, with Medicare and NHS access shaping pace and affordability. Private prescriptions and new formulations are widening access while competition accelerates.
What's behind the headline?
Insightful take
- The momentum comes from patient demand and payer policy changes that remove cost barriers.
- Companies are racing to diversify formats (pills, injections, combo therapies) to fit patient preferences and healthcare systems.
- Expect continued rapid development, including new once-daily or monthly regimens, and broader indications beyond obesity.
Forecast
- Access will depend on pricing and coverage decisions; without Medicare/NHS alignment, adoption may stall in some markets.
- Private-sector uptake will likely rise, but clinicians will need to balance counseling, dosing, and side effects as patients shift to oral options.
How we got here
The global rollout of GLP-1 obesity drugs is accelerating, with several manufacturers pursuing pills and injections. In the US, the private market and Medicare policy are driving uptake; in the UK and UAE, regulators are approving oral forms and expanding access. Industry players foresee a continuing wave of new formats and broader patient access.
Our analysis
Bloomberg notes J&J stepping back from obesity drugs to focus on cancer; Axios covers looming Medicare coverage constraints and prior authorizations; CNBC and Reuters report on Wegovy pills gaining market traction in the US and UK; The Guardian and Reuters provide NHS/NHS-adjacent perspectives on UK access.
Go deeper
- Which country will have the fastest uptake of Wegovy pills, injections or other GLP-1s?
- How will oral GLP-1s influence physician prescribing and patient adherence?
- What price points and coverage shifts are most likely to determine access in 2026–27?
More on these topics
-
Novo Nordisk - Danish pharmaceutical company
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S (wholly owned by the Novo Nordisk Foundation) which holds approximately 28.1% of its shares and a majority (77.1%) of its voting shares. Novo Nordisk manufactures and markets pharmaceutical products and services, specifically diabetes and obesity medications and devices. Novo Nordisk employs more than 48,000 people globally, and markets its products in 168 countries. The corporation was created in 1989, through a merger of two Danish companies, which date back to the 1920s. Novo Nordisk is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA). The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo Nordisk was named the most sustainable company in the world by the business magazine Corporate Knights, while spin-off company Novozymes was named fourth. It is a leader in the FTSE4Good Index, and the only European company in the top ten. Novo Nordisk is the largest pharmaceutical company...
-
Eli Lilly and Company - Pharmaceutical company
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by, and named after, Col. Eli Lilly, a
-
Medicare - Wikimedia disambiguation page
Medicare is a government national health insurance program in the United States, begun in 1965 under the Social Security Administration and now administered by the Centers for Medicare and Medicaid Services.
-
American Diabetes Association - U.S.-based nonprofit organization
The American Diabetes Association (ADA) is a United States–based nonprofit that seeks to educate the public about diabetes and to help those affected by it through funding research to manage, cure and prevent diabetes, including type 1 diabetes, type...